Bengbu Fengyuan Pharmaceutical Co., Ltd.

This product belongs to the macrolide antibiotics. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), all groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, certain spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on certain bacteria at high concentrations. It can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site ("P" site), blocking the transfer RNA (t-RNA) from binding to the "P" site, and also blocking the self-acceptor site ("A" site) of the polypeptide chain.

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase (bacterial topoisomerase II) and hinder bacterial DNA replication. It has good antibacterial effects on most Enterobacteriaceae, some Gram-positive bacteria, Legionella, mycoplasma, and Chlamydia, but has poor effects on anaerobic bacteria and enterococci.

This product is a dopamine 2 (D2) receptor antagonist, and also has a 5-hydroxytryptamine 4 (5-HT4) receptor agonist effect, and has a mild inhibitory effect on 5-HT3 receptors. It can act on dopamine receptors in the medullary chemo-emetic zone (CTZ) to increase the threshold of CTZ, and has a strong central antiemetic effect. This product can also block hypothalamic dopamine receptors, inhibit prolactin inhibitory factor, and promote the secretion of prolactin, so it has a certain lactation effect. The inhibitory effect on other parts of the central nervous system is relatively small, with a weak sedative effect and less hypnotic effect. The main effect on the gastrointestinal tract is on the upper digestive tract, promoting the movement of the stomach and upper intestinal segments; increasing the tension of the gastrointestinal sphincter in the resting state, increasing the tension and contraction amplitude of the lower esophageal sphincter, increasing the pressure at the lower end of the esophagus, blocking gastroesophageal reflux, strengthening gastric and esophageal peristalsis, and enhancing the ability to clear the contents of the esophagus, promoting gastric emptying; promoting the relaxation of the pylorus, duodenum and upper jejunum, forming functional coordination between the gastric antrum, gastric body and upper small intestine. These effects can also enhance the antiemetic effect of this product. The transmission effect of this product on the small intestine and colon is still uncertain.

No specific pharmacological effects mentioned

Proton pump inhibitor. This product is a fat-soluble weakly alkaline drug that is easily concentrated in an acidic environment. Therefore, after oral administration, it can be specifically distributed in the secretory tubules of the gastric mucosal parietal cells and converted into the active form of sulfenamide in this high-acid environment. Then, it irreversibly combines with the sulfhydryl group of the H,K-ATPase (also known as the proton pump) in the secretory membrane of the parietal cells through a disulfide bond to form a complex of sulfenamide and the proton pump, thereby inhibiting the activity of the enzyme and blocking the final step of gastric acid secretion. Therefore, this product has a strong and lasting inhibitory effect on gastric acid secretion caused by various reasons.